Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens

March 9, 2026 5:24 AM EDT Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $10.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login